Business Context and Reporting Period
This Form 6-K filing by Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) was submitted on February 9, 2026. The document serves as a notice convening the Annual General Shareholders' Meeting scheduled for March 19, 2026, in Bilbao, Spain. The meeting agenda focuses on the approval of financial statements and corporate management for the fiscal year ended December 31, 2025.
Key Financial Metrics
The filing text does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt levels, or liquidity ratios for the 2025 fiscal year. These figures are scheduled for approval by shareholders at the upcoming meeting but are not disclosed in this notice.
Material Changes and Capital Actions
- Capital Issuance Authorization: Shareholders are asked to authorize the Board to issue Contingently Convertible Securities (CoCos) up to a maximum of EUR 8 billion over a five-year period.
- Share Buyback and Reduction: The agenda includes approval for the derivative acquisition of own shares and a subsequent reduction of share capital by up to 10% through the redemption of these shares.
- Board Composition: The meeting will address the re-election of four directors (Sonia Lilia Dulá, Raúl Catarino Galamba de Oliveira, Ana Leonor Revenga Shanklin, Carlos Vicente Salazar Lomelín) and the appointment of one new director (Jorge Montalbo Todolí).
Guidance, Outlook, and Governance
Management commentary and forward-looking guidance regarding financial performance are not included in this filing. Key governance and risk-related items on the agenda include:
- Remuneration Policy: Approval of the Directors' Remuneration Policy and a variable remuneration cap of up to 200% of the fixed component for employees with significant risk impact.
- Auditor Re-election: Re-election of Ernst & Young, S.L. as the external auditor for the 2026 financial year.
- Non-Financial Reporting: Approval of the non-financial information report for the 2025 fiscal year.
Investor Verification Checklist
- Verify the final approval of the 2025 Annual Financial Statements and the specific allocation of results at the March 19, 2026 meeting.
- Confirm the execution details of the EUR 8 billion CoCo issuance authorization and any impact on capital structure.
- Monitor the implementation of the share capital reduction (up to 10%) and the timeline for the redemption of own shares.
- Review the full text of the approved Remuneration Policy and the specific variable pay caps for risk-sensitive roles.